SEC Form 4 · accession 0001209191-18-037121
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristine C. Mechem
Officer — VP of Marketing
Period of report
Jun 7, 2018
Accepted (ET)
Jun 11, 2018 · 7:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $2.85 | Jun 7, 2018 | A | 50,000 | A | — | Jun 6, 2028 | Common Stock | 50,000 | 50,000 | D |
| Option to Purchase Common StockF2 | $2.35 | holding | — | — | — | — | May 22, 2028 | Common Stock | 125,000 | 125,000 | D |
| Option to Purchase Common StockF3 | $4.70 | holding | — | — | — | — | Feb 16, 2027 | Common Stock | 67,500 | 67,500 | D |
| Option to Purchase Common StockF4 | $3.06 | holding | — | — | — | — | Feb 15, 2026 | Common Stock | 60,000 | 60,000 | D |
| Option to Purchase Common StockF5 | $3.16 | holding | — | — | — | — | Aug 3, 2025 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1One half of these options shall vest on the filing of the Medicare dossier for the Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date, and the balance shall vest on the date of return from sabbatical and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date.
- F2These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
- F3One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- F4One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- F5One quarter of the options vested on August 3, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.